Canopus BioPharma (OTCPK:CBIA) - Stock Price, News & Analysis

CBIA Stock Overview

A pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. More details

CBIA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($390K)

Shareholders have been substantially diluted in the past year

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the US market

Canopus BioPharma Incorporated Competitors

Kid Castle Educational

OTCPK:KDCE

US$357.2k

AmeriCann

OTCPK:ACAN

US$465.9k

SciSparc

NasdaqCM:SPRC

US$790.0k

TFF Pharmaceuticals

NasdaqCM:TFFP

US$1.4m

Price History & Performance

Summary of all time highs, changes and price drops for Canopus BioPharma
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0015
52 Week Low	US$0.0001
Beta	0
11 Month Change	0%
3 Month Change	0%
1 Year Change	-84.62%
33 Year Change	-99.90%
5 Year Change	-99.92%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	CBIA	US Pharmaceuticals	US Market
7D	-50.0%	2.6%	0.5%
1Y	-84.6%	13.1%	30.7%

Return vs Industry: CBIA underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.

Return vs Market: CBIA underperformed the US Market which returned 32.3% over the past year.

Price Volatility

Is CBIA's price volatile compared to industry and market?
CBIA volatility
CBIA Average Weekly Movement	94.3%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CBIA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CBIA's weekly volatility has increased from 69% to 94% over the past year.

About the Company

Founded	Employees	CEO	Website
1996	n/a	Patrick Prendergast	n/a

Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007.

Canopus BioPharma Incorporated Fundamentals Summary

How do Canopus BioPharma's earnings and revenue compare to its market cap?
CBIA fundamental statistics
Market cap	US$389.85k
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is CBIA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CBIA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CBIA perform over the long term?

See historical performance and comparison

Canopus BioPharma OTCPK:CBIA Stock Report